Johnson & Johnson (ETR:JNJ)
164.94
-0.06 (-0.04%)
Oct 10, 2025, 5:35 PM CET
Johnson & Johnson Revenue
In the year 2024, Johnson & Johnson had annual revenue of $88.82B USD with 4.30% growth. Johnson & Johnson had revenue of $23.74B in the quarter ending June 29, 2025, with 5.77% growth.
Revenue
$88.82B
Revenue Growth
+10.26%
P/S Ratio
5.11
Revenue / Employee
$643.16K
Employees
138,100
Market Cap
395.15B EUR
Revenue Chart
* This company reports financials in USD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 29, 2024 | 88.82B | 3.66B | 4.30% |
Dec 31, 2023 | 85.16B | 5.17B | 6.46% |
Jan 1, 2023 | 79.99B | 1.25B | 1.59% |
Jan 2, 2022 | 78.74B | -3.84B | -4.65% |
Jan 3, 2021 | 82.58B | 525.00M | 0.64% |
Dec 29, 2019 | 82.06B | 478.00M | 0.59% |
Dec 30, 2018 | 81.58B | 5.13B | 6.71% |
Dec 31, 2017 | 76.45B | 4.56B | 6.34% |
Jan 1, 2017 | 71.89B | 1.82B | 2.59% |
Jan 3, 2016 | 70.07B | -4.26B | -5.73% |
Dec 28, 2014 | 74.33B | 3.02B | 4.23% |
Dec 29, 2013 | 71.31B | 4.09B | 6.08% |
Dec 30, 2012 | 67.22B | 2.19B | 3.37% |
Jan 1, 2012 | 65.03B | 3.44B | 5.59% |
Jan 2, 2011 | 61.59B | -310.00M | -0.50% |
Jan 3, 2010 | 61.90B | -1.85B | -2.90% |
Dec 28, 2008 | 63.75B | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Siemens Healthineers AG | 23.38B |
Merck KGaA | 21.22B |
Bayer Aktiengesellschaft | 46.17B |
Fresenius SE & Co. KGaA | 22.28B |
Fresenius Medical Care AG | 19.52B |
Sartorius Aktiengesellschaft | 3.47B |
Fielmann Group AG | 2.40B |
Carl Zeiss Meditec AG | 2.18B |
Johnson & Johnson News
- 1 day ago - 3 Defensive Stocks to Watch as Trade Tensions Resurface: GILD, JNJ, KR - Nasdaq
- 1 day ago - US FDA adds boxed warning to J&J, Legend Biotech's cancer therapy - Reuters
- 1 day ago - Q3 Earnings Season Setup Remains Favorable: What to Know - Nasdaq
- 1 day ago - Johnson & Johnson (JNJ) Advises Against Tutanota's Tender Offer - GuruFocus
- 1 day ago - Johnson & Johnson (JNJ) Advises Against Tutanota's Mini-Tender Offer - GuruFocus
- 1 day ago - Johnson & Johnson recommends shareholders reject “mini-tender” offer by Tutanota - Wallstreet:Online
- 1 day ago - Johnson & Johnson recommends shareholders reject “mini-tender” offer by Tutanota - Business Wire
- 1 day ago - JNJ: Morgan Stanley Maintains Rating, Slight Increase in Price Target | JNJ Stock News - GuruFocus